Acta Diabetologica

, Volume 55, Issue 5, pp 461–468 | Cite as

Comparative evaluation of pharmacokinetics and pharmacodynamics of insulin glargine (Glaritus®) and Lantus® in healthy subjects: a double-blind, randomized clamp study

  • Ashima Bhatia
  • Shraddha Tawade
  • Mushtaque Mastim
  • Eliford Ngaimisi Kitabi
  • Mathangi Gopalakrishnan
  • Manish Shah
  • Sridhar Yeshamaina
  • Joga Gobburu
  • Maharaj Sahib
  • Dipak Thakur
  • K. M. Prasanna Kumar
Original Article



The objective of the study was to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of an insulin glargine formulation, Glaritus® (test) with the innovator’s formulation Lantus® (reference) using the euglycemic clamp technique in a single-dose, double-blind, randomized, two sequences, four-period replicate crossover study in healthy volunteers (n = 40).


Subjects received subcutaneous administration of the insulin glargine (0.4 IU/kg) formulation at two occasions for test and reference and a 20% glucose solution was infused at variable rate to maintain euglycemia for 24 h.


Both PK [area under the plasma concentration time curve (AUC0–24 h) and maximum insulin concentration (Cmax)] and PD endpoints [area under glucose infusion rate time curve (AUCGIR0–24) and maximum glucose infusion rate (GIRmax)] demonstrated bioequivalence of Glaritus to Lantus with the 90% confidence interval of geometric mean ratio of test to reference entirely contained within 0.80–1.25. Both formulations showed equivalent geometric least-square mean LSM value (0.08 nmol/L) for Cmax. The geometric LSM AUC0–24 h value for Glaritus® (1.09 h nmol/L) was comparable to Lantus (1.05 h nmol/L). Median Tmax values were also identical (12 h for both), and median t1/2 values were also equal (18 h for both). For GIRTmax, the difference between the means for the two was not statistically significant. No AEs related to study formulations were reported, and both products were well tolerated.


The test product (Glaritus) was found to be bioequivalent to the reference product (Lantus).

Clinical trial registration number



Insulin glargine Pharmacokinetics Pharmacodynamics Bioequivalence Diabetes mellitus 



The authors also acknowledge Veeda Clinical Research for conduct of the study, Manipal Acunova for analysis of PK samples and Devdutt Pathare for monitoring the study.

Authors’ contribution

Eliford Ngaimisi contributed to data analysis and manuscript writing. Mathangi Gopalakrishnan contributed to data analysis and manuscript writing. Joga Gobburu contributed to manuscript writing. Prasanna Kumar analyzed and interpreted the data. Ashima Bhatia contributed to the study methodology and procedures and data interpretation, Shraddha Tawade, Mushtaque Mastim, Sridhar Yeshamaina and Manish Shah were involved in study design, data collection, data analysis and interpretation. Maharaja Sahib and Dipak Thakur contributed to the development of bioanalysis method of Glargine. All the authors approved the final draft of the manuscript after critical review and revision.

Compliance with ethical standards

Conflict of interest

Prasanna Kumar K M is an advisory board member of Wockhardt, Sanofi, Biocon, Novo- Nordisk and Eli Lilly and has conducted clinical research as PI for the insulin analogs for these companies. Shraddha Tawade, Mushtaque Mastim, Manish Shah, Sridhar Yeshamaina, Maharaja Sahib, Dipak Thakur and Ashima Bhatia are employees of Wockhardt Ltd. Eliford Ngaimisi, Mathangi Gopalakrishnan and Joga Gobburu have no conflict of interest to declare.

Ethical approval

The study was conducted in accordance with the declaration of Helsinki and as per the guidelines formulated by the ICH GCP and the Indian Council of Medical Research (ICMR) for biomedical research on human subjects.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

592_2018_1113_MOESM1_ESM.docx (353 kb)
Supplementary material 1 (DOCX 352 kb)


  1. 1.
    Owens DR, Landgraf W, Schmidt A et al (2012) The emergence of biosimilar insulin preparations—a cause for concern? Diabetes Technol Ther 14:989–996. CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Lepore M, Pampanelli S, Fanelli C et al (2000) Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49:2142–2148CrossRefPubMedGoogle Scholar
  3. 3.
    Scholtz HE, Pretorius SG, Wessels DH, Becker RHA (2005) Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48:1988–1995. CrossRefPubMedGoogle Scholar
  4. 4.
    Rotenstein LS, Ran N, Shivers JP et al (2012) Opportunities and challenges for biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes 30:138–150CrossRefGoogle Scholar
  5. 5.
    Ratner RE, Hirsch IB, Neifing JL et al (2000) Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. US Study Group of Insulin Glargine in Type 1 Diabetes. Diabetes Care 23:639–643CrossRefPubMedGoogle Scholar
  6. 6.
    Ashwell SG, Amiel SA, Bilous RW (2006) Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. Diabet Med 23:285–292CrossRefPubMedGoogle Scholar
  7. 7.
    Barnett AH (2006) Insulin glargine in the treatment of type 1 and type 2 diabetes. Vasc Health Risk Manag 2:59CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Rys P, Wojciechowski P, Rogoz-Sitek A et al (2015) Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 52:649–662. CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Pérez-Maraver M, Caballero-Corchuelo J, Boltana A et al (2013) Comparison of human insulin and insulin analogues on hypoglycaemia and metabolic variability in type 1 diabetes using standardized measurements (HYPO score and Lability Index). Acta Diabetol 50:529–535. CrossRefPubMedGoogle Scholar
  10. 10.
    Cigrovski Berkovic M, Petrovski G, Grulovic N (2016) Effectiveness of insulin glargine in type 2 diabetes mellitus patients failing glycaemic control with premixed insulin: adriatic countries data meta-analysis. Acta Diabetol 53:709–715. CrossRefPubMedGoogle Scholar
  11. 11.
    Hasani-Ranjbar S, Fazlollahi MR, Mehri A, Larijani B (2012) Allergy to human insulin and specific immunotherapy with glargine; case report with review of literature. Acta Diabetol 49:69–73. CrossRefPubMedGoogle Scholar
  12. 12.
    Akinci B, Yener S, Bayraktar F, Yesil S (2010) Allergic reactions to human insulin: a review of current knowledge and treatment options. Endocrine 37:33–39. CrossRefPubMedGoogle Scholar
  13. 13.
    Heinzerling L, Raile K, Rochlitz H et al (2008) Insulin allergy: clinical manifestations and management strategies: insulin allergy. Allergy 63:148–155. CrossRefPubMedGoogle Scholar
  14. 14.
    Puppalwar G, Sawant S, Silgiri B et al (2017) Evaluation of Safety and Efficacy of Glaritus® versus Lantus® in Combination with Insulin Lispro among Adults with Type 1 Diabetes Mellitus-Phase IV Study. Open J Endocr Metab Dis 07:111–125. CrossRefGoogle Scholar
  15. 15.
    Bhuiyan PS, Rege NN (2001) ICH harmonised tripartite guideline: guideline for good clinical practice. J Postgrad Med 47:45–50Google Scholar
  16. 16.
    GUIDELINE FOR GOOD CLINICAL PRACTICE - E6_R1_Guideline.pdf. Accessed 3 Aug 2017
  17. 17.
    Linnebjerg H, Lam ECQ, Seger ME et al (2015) Comparison of the pharmacokinetics and pharmacodynamics of LY2963016 insulin glargine and EU- and US-approved versions of Lantus insulin glargine in healthy subjects: three randomized euglycemic clamp studies. Diabetes Care 38:2226–2233. CrossRefPubMedGoogle Scholar
  18. 18.
    Heise T, Nosek L, Rønn BB et al (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53:1614–1620CrossRefPubMedGoogle Scholar
  19. 19.
    Lucidi P, Porcellati F, Candeloro P et al (2014) Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: a dose–response study. Nutr Metab Cardiovasc Dis 24:709–716. CrossRefPubMedGoogle Scholar
  20. 20.
    Requirements and guidelines for permission to import and/or manufacture of new drugs for sale or to undertake clinical trials. In: Cent. Drugs Stand. Control Organ. Website New Delhi India. Accessed 17 Aug 2017
  21. 21.
    Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues - WC500184161.pdf. Accessed 3 Aug 2017
  22. 22.
    Bequette BW (2009) Glucose clamp algorithms and insulin time-action profiles. J Diabetes Sci Technol 3:1005–1013. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2018

Authors and Affiliations

  • Ashima Bhatia
    • 1
  • Shraddha Tawade
    • 1
  • Mushtaque Mastim
    • 1
  • Eliford Ngaimisi Kitabi
    • 2
  • Mathangi Gopalakrishnan
    • 2
  • Manish Shah
    • 1
  • Sridhar Yeshamaina
    • 1
  • Joga Gobburu
    • 2
  • Maharaj Sahib
    • 3
  • Dipak Thakur
    • 3
  • K. M. Prasanna Kumar
    • 4
  1. 1.Wockhardt, Global Clinical DevelopmentMumbaiIndia
  2. 2.School of Pharmacy, Center for Translational MedicineUniversity of MarylandBaltimoreUSA
  3. 3.Wockhardt, Research CenterAurangabadIndia
  4. 4.Centre for Diabetes and Endocrine CareBengaluruIndia

Personalised recommendations